These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Review and reassessment of dosing schedules for cefotaxime in selected medical indications. Young LS Diagn Microbiol Infect Dis; 1995; 22(1-2):147-54. PubMed ID: 7587030 [TBL] [Abstract][Full Text] [Related]
23. [Cefotaxime in infections caused by multi-resistant microorganisms]. Aguirre M; Torres A; Alés JM Rev Clin Esp; 1981 Jan; 160(1):15-8. PubMed ID: 6259703 [No Abstract] [Full Text] [Related]
27. Cefotaxime in the treatment of severe paediatric infections. Papadatos CJ; Kafetzis DA; Kanarios J J Antimicrob Chemother; 1980 Sep; 6 Suppl A():243-8. PubMed ID: 6252164 [No Abstract] [Full Text] [Related]
28. The role of the new penicillins and cephalosporins in the management of infection in granulocytopenic patients. Klastersky J Schweiz Med Wochenschr Suppl; 1983; 14():64-9. PubMed ID: 6361994 [TBL] [Abstract][Full Text] [Related]
29. Cefotaxime in the treatment of prophylaxis of surgical infections. Wittmann DH; Jones RN; Malledant J; Privitera G J Chemother; 1997 May; 9 Suppl 2():19-33. PubMed ID: 9248973 [TBL] [Abstract][Full Text] [Related]
30. Cefotaxime therapy in children with serious infections associated with reduced host defense mechanisms. López EL; Bonesana NF; Rubeglio E; Schugurensky A; Sommersguter G; Grinstein S J Antimicrob Chemother; 1980 Sep; 6 Suppl A():249-53. PubMed ID: 6252165 [No Abstract] [Full Text] [Related]
31. [Diffusion of cephazolin in the biliary tract]. Brogard JM; Dorner M; Haegele P; Meyer C; Lavillaureix J Nouv Presse Med; 1974 Apr; 3(0):24-8. PubMed ID: 4600176 [No Abstract] [Full Text] [Related]
32. Efficacy and safety of cefotaxime in the management of pediatric infections. Jacobs RF Infection; 1991; 19 Suppl 6():S330-6. PubMed ID: 1791079 [TBL] [Abstract][Full Text] [Related]
33. [New cephalosporins]. Solberg CO Tidsskr Nor Laegeforen; 1974 Oct; 94(30):2099-101. PubMed ID: 4417025 [No Abstract] [Full Text] [Related]
34. Clinical experience with oral cephradine. Martin RR J Ir Med Assoc; 1973 Mar; Suppl():25-8. PubMed ID: 4572640 [No Abstract] [Full Text] [Related]
35. Microbiology of oral cephalosporins. Cullmann W Antibiot Chemother (1971); 1995; 47():72-109. PubMed ID: 8554308 [No Abstract] [Full Text] [Related]
36. Advances in the treatment of gram-negative bacterial meningitis. Romankiewicz N J Pract Nurs; 1984 Dec; 34(2):59-61. PubMed ID: 6444163 [No Abstract] [Full Text] [Related]
37. Use of third-generation cephalosporins for treatment of neonatal infections. McCracken GH Am J Dis Child; 1985 Nov; 139(11):1079-80. PubMed ID: 4061402 [No Abstract] [Full Text] [Related]
38. The newest cephalosporins: how to use them? Ehrenkranz NJ; Hoffman TA J Fla Med Assoc; 1982 Oct; 69(10):863-4. PubMed ID: 6292322 [No Abstract] [Full Text] [Related]
39. Seminar on antibiotics IV. The cephalosporins. Rhoades ER J Okla State Med Assoc; 1980 Oct; 73(10):360-2. PubMed ID: 7431140 [No Abstract] [Full Text] [Related]
40. Pharmacokinetics of cefotaxime in neonates and children: clinical aspects. von Hattingberg HM; Marget W; Belohradsky BH; Roos R J Antimicrob Chemother; 1980 Sep; 6 Suppl A():113-8. PubMed ID: 6252139 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]